NCT05038098Not yet recruitingPhase 1
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in combination with the indocyanine green dye may help researchers better detect the disease.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 27 Aug 2021
- Start date
- 31 Dec 2026
- Primary completion date
- 2 Feb 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05038098
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- From 31 Dec 2026 to the primary completion date, 2 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to surgery +/- adjuvant therapy
Other illness
- Allergy or intolerance to iron oxide compounds
- Allergy or intolerance to iodides
- Iron overload disorder
Other
- Pregnant or lactating women\*
- Use of contraception is required for females during the study. Male patients who are sexually active with a female of childbearing potential are allowed for study enrollment and will not require use of contraception
Who the study is looking for
- Age 18 or older
- Willing to provide informed consent
- Biopsy proven gastric cancer, undergoing curative-intent gastrectomy
- No distant metastases
- Pathologic diagnosis of gastric adenocarcinoma
- Pre-treatment endoscopic measurement of less than or equal to 4 cm in diameter of the gastric cancer
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.